Lorenzo Capitani
Overview
Explore the profile of Lorenzo Capitani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hopkins G, Gomez N, Tucis D, Bartlett L, Steers G, Burns E, et al.
J Clin Immunol
. 2024 Jun;
44(6):147.
PMID: 38856804
Purpose: Asymptomatic SARS-CoV-2 infections were widely reported during the COVID-19 pandemic, acting as a hidden source of infection. Many existing studies investigating asymptomatic immunity failed to recruit true asymptomatic individuals....
2.
Scurr M, Lippiatt G, Capitani L, Bentley K, Lauder S, Smart K, et al.
Nat Commun
. 2022 Sep;
13(1):5422.
PMID: 36130936
T cells specific for SARS-CoV-2 are thought to protect against infection and development of COVID-19, but direct evidence for this is lacking. Here, we associated whole-blood-based measurement of SARS-CoV-2-specific interferon-γ-positive...
3.
Burnell S, Capitani L, MacLachlan B, Mason G, Gallimore A, Godkin A
Immunother Adv
. 2022 Mar;
2(1):ltab025.
PMID: 35265944
Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4....
4.
Scurr M, Zelek W, Lippiatt G, Somerville M, Burnell S, Capitani L, et al.
Immunology
. 2021 Nov;
165(2):250-259.
PMID: 34775604
Accurate assessment of SARS-CoV-2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS-CoV-2-specific T-cell responses are...
5.
Teijeira Crespo A, Burnell S, Capitani L, Bayliss R, Moses E, Mason G, et al.
Immunology
. 2021 Feb;
163(4):389-398.
PMID: 33638871
Oncolytic viruses possess the ability to infect, replicate and lyse malignantly transformed tumour cells. This oncolytic activity amplifies the therapeutic advantage and induces a form of immunogenic cell death, characterized...
6.
Hanna S, Codd A, Gea-Mallorqui E, Scourfield D, Richter F, Ladell K, et al.
Oxf Open Immunol
. 2021 Feb;
2(1):iqaa007.
PMID: 33575657
COVID-19 is characterized by profound lymphopenia in the peripheral blood, and the remaining T cells display altered phenotypes, characterized by a spectrum of activation and exhaustion. However, antigen-specific T cell...
7.
Cowan G, Miles K, Capitani L, Giguere S, Johnsson H, Goodyear C, et al.
Front Immunol
. 2020 Apr;
11:395.
PMID: 32265907
B cells are critical for promoting autoimmunity and the success of B cell depletion therapy in rheumatoid arthritis (RA) confirms their importance in driving chronic inflammation. Whilst disease specific autoantibodies...